*Timothy Allen Department Of Oncology, Enter For Excellence In Research And Development, United States
*Corresponding Author: Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States Email:Timothy.Allen@gapsos.com
Published on: 2017-06-29
Acute myeloid leukemia (AML) is cancer of the blood cells. This cancer specifically affects red blood cells, platelet forming cells and other white blood cells in the body; its incidence is very low in the United States with less than 3% of cancer diagnoses being for AML. Traditionally, this disease would be treated with chemotherapy or radiation therapy. Immunotherapy is a new way to fight this cancer. This therapy stimulates one’s own immune system to fight the malignant tumor. In this paper, we discuss the causes, epidemiology, and potential immunotherapeutic techniques to fight AML.
Acute Myeloid Leukemia (AML) represents less than 3% of all cancers. According to data collected in the United States (US) in 2010, AML has an age-standardized rate of incidence of 23.5 per 100,000. In 2009, the overall five year survival rate of 24.9% was estimated in the US. According to the American Cancer Society, in 2014 more than 18,860 new cases of AML were diagnosed in the US. In the same year, 10,460 cases of death were also reported. The US, Australia, and west European countries have a higher incidence rate in comparison with the other countries.